These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 19260105)

  • 1. Paraphilia and other disturbed behavior associated with dopamimetic treatment for Parkinson's disease.
    Nielssen OB; Cook RJ; Joffe R; Meagher LJ; Silberstein P
    Mov Disord; 2009 May; 24(7):1091-2. PubMed ID: 19260105
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopaminergic drugs, paraphilic fantasies, paraphilic behaviours and creativity in Parkinson's disease.
    Cannas A; Solla P; Floris GL; Serra C; Costantino E; Piras V; Marrosu F; Marrosu MG
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):563-4. PubMed ID: 20153398
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopa-responsive pseudo-orthostatic tremor in parkinsonism.
    Thomas A; Bonanni L; Antonini A; Barone P; Onofrj M
    Mov Disord; 2007 Aug; 22(11):1652-6. PubMed ID: 17579364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of dopa-responsive parkinsonian syndrome and motor neuron disease.
    Pinkhardt EH; Sperfeld AD; Gdynia HJ; Ludolph AC; Kassubek J
    Neurodegener Dis; 2009; 6(3):95-101. PubMed ID: 19270441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early dopasensitive Parkinsonism related to myotonic dystrophy type 2.
    Annic A; Devos D; Destée A; Defebvre L; Lacour A; Hurtevent JF; Stojkovic T
    Mov Disord; 2008 Oct; 23(14):2100-1. PubMed ID: 18759330
    [No Abstract]   [Full Text] [Related]  

  • 6. Impulse control disorders and punding in Perry syndrome.
    Mishima T; Fujioka S; Kurisaki R; Yanamoto S; Higuchi MA; Tsugawa J; Fukae J; Neshige R; Tsuboi Y
    Parkinsonism Relat Disord; 2015 Nov; 21(11):1381-2. PubMed ID: 26411500
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of hypersexuality in Parkinson's disease with carbamazepine--a case report.
    Bach JP; Oertel WH; Dodel R; Jessen F
    Mov Disord; 2009 Jun; 24(8):1241-2. PubMed ID: 19309760
    [No Abstract]   [Full Text] [Related]  

  • 8. Sex, immorality, and mental disorders.
    Gert B; Culver CM
    J Med Philos; 2009 Oct; 34(5):487-95. PubMed ID: 19690325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine dysregulation syndrome in a patient with restless legs syndrome.
    Leu-Semenescu S; Karroum E; Brion A; Konofal E; Arnulf I
    Sleep Med; 2009 Apr; 10(4):494-6. PubMed ID: 19410183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of paraphilia with an analogue of gonadotropin-releasing hormone.
    Windhaber J; Eher R
    N Engl J Med; 1998 Jun; 338(26):1923; author reply 1923-4. PubMed ID: 9643990
    [No Abstract]   [Full Text] [Related]  

  • 11. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
    Ballion B; Frenois F; Zold CL; Chetrit J; Murer MG; Gonon F
    Neurobiol Dis; 2009 Sep; 35(3):376-84. PubMed ID: 19501163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine agonist: pathological gambling and hypersexuality.
    Prescrire Int; 2008 Oct; 17(97):200-1. PubMed ID: 19536937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease.
    Fenu S; Wardas J; Morelli M
    Behav Pharmacol; 2009 Sep; 20(5-6):363-79. PubMed ID: 19724195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow wave sleep and dopaminergic treatment in Parkinson's disease: a polysomnographic study.
    Diederich NJ; Paolini V; Vaillant M
    Acta Neurol Scand; 2009 Nov; 120(5):308-13. PubMed ID: 19485952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
    Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
    Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
    Kim S; Moon M; Park S
    J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TREATMENT OF SEVERE PARKINSON'S SYNDROME WITH ORPHENADRINE WITH SPECIAL REFERENCE TO MENTAL ACTIVITY].
    BAUER H
    Med Klin; 1963 Sep; 58():1523-6. PubMed ID: 14054489
    [No Abstract]   [Full Text] [Related]  

  • 19. [Parkinson's syndrome after acute severe acrylonitrile poisoning in one patient].
    Fei N; Xu LZ
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 May; 24(5):309-10. PubMed ID: 16737605
    [No Abstract]   [Full Text] [Related]  

  • 20. Dopamine agonists and therapy compliance.
    Grosset D
    Neurol Sci; 2008 Dec; 29 Suppl 5():S375-6. PubMed ID: 19381766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.